Review



d6g6 anti-excision repair cross-complementation 1 (ercc1) monoclonal antibody  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc d6g6 anti-excision repair cross-complementation 1 (ercc1) monoclonal antibody
    Consolidated Standards of Reporting Trials diagram. <t>ERCC1,</t> excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.
    D6g6 Anti Excision Repair Cross Complementation 1 (Ercc1) Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d6g6 anti-excision repair cross-complementation 1 (ercc1) monoclonal antibody/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    d6g6 anti-excision repair cross-complementation 1 (ercc1) monoclonal antibody - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial"

    Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

    Journal: ESMO Open

    doi: 10.1016/j.esmoop.2021.100249

    Consolidated Standards of Reporting Trials diagram. ERCC1, excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.
    Figure Legend Snippet: Consolidated Standards of Reporting Trials diagram. ERCC1, excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.

    Techniques Used: Immunohistochemistry

    Survival outcomes according to excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TS) expression. (A) Immunohistochemistry for TS expression in soft tissue sarcoma (STS). Representative images of both TS-negative (H-score: 0, ×200) and TS-positive (H-score: 10 and 200, ×200) sections. (B) Immunohistochemistry for ERCC1 expression in sections from patients with STS. Representative images of ERCC1-negative (H-score: 0, ×200) and ERCC1-positive sections (H-score: 15 and 200, ×200). (C) Kaplan–Meier analysis of overall survival (OS) according to TS expression, determined using a cut-off point of median H-score 25. (D) Kaplan–Meier analysis of OS according to ERCC1 expression, determined using a cut-off point of median H-score 60.
    Figure Legend Snippet: Survival outcomes according to excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TS) expression. (A) Immunohistochemistry for TS expression in soft tissue sarcoma (STS). Representative images of both TS-negative (H-score: 0, ×200) and TS-positive (H-score: 10 and 200, ×200) sections. (B) Immunohistochemistry for ERCC1 expression in sections from patients with STS. Representative images of ERCC1-negative (H-score: 0, ×200) and ERCC1-positive sections (H-score: 15 and 200, ×200). (C) Kaplan–Meier analysis of overall survival (OS) according to TS expression, determined using a cut-off point of median H-score 25. (D) Kaplan–Meier analysis of OS according to ERCC1 expression, determined using a cut-off point of median H-score 60.

    Techniques Used: Expressing, Immunohistochemistry



    Similar Products

    d6g6 anti-excision repair cross-complementation 1 (ercc1) monoclonal antibody  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc d6g6 anti-excision repair cross-complementation 1 (ercc1) monoclonal antibody
    Consolidated Standards of Reporting Trials diagram. <t>ERCC1,</t> excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.
    D6g6 Anti Excision Repair Cross Complementation 1 (Ercc1) Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d6g6 anti-excision repair cross-complementation 1 (ercc1) monoclonal antibody/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    d6g6 anti-excision repair cross-complementation 1 (ercc1) monoclonal antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Consolidated Standards of Reporting Trials diagram. ERCC1, excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.

    Journal: ESMO Open

    Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

    doi: 10.1016/j.esmoop.2021.100249

    Figure Lengend Snippet: Consolidated Standards of Reporting Trials diagram. ERCC1, excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.

    Article Snippet: Immunohistochemical staining was carried out using the D6G6 anti-excision repair cross-complementation group 1 (ERCC1) monoclonal antibody (Cell Signaling Technology, Danvers, MA), the TS106 anti-TS monoclonal antibody (Dako, Glostrup, Denmark), and a DAKO Link 48 system (Dako).

    Techniques: Immunohistochemistry

    Survival outcomes according to excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TS) expression. (A) Immunohistochemistry for TS expression in soft tissue sarcoma (STS). Representative images of both TS-negative (H-score: 0, ×200) and TS-positive (H-score: 10 and 200, ×200) sections. (B) Immunohistochemistry for ERCC1 expression in sections from patients with STS. Representative images of ERCC1-negative (H-score: 0, ×200) and ERCC1-positive sections (H-score: 15 and 200, ×200). (C) Kaplan–Meier analysis of overall survival (OS) according to TS expression, determined using a cut-off point of median H-score 25. (D) Kaplan–Meier analysis of OS according to ERCC1 expression, determined using a cut-off point of median H-score 60.

    Journal: ESMO Open

    Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

    doi: 10.1016/j.esmoop.2021.100249

    Figure Lengend Snippet: Survival outcomes according to excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TS) expression. (A) Immunohistochemistry for TS expression in soft tissue sarcoma (STS). Representative images of both TS-negative (H-score: 0, ×200) and TS-positive (H-score: 10 and 200, ×200) sections. (B) Immunohistochemistry for ERCC1 expression in sections from patients with STS. Representative images of ERCC1-negative (H-score: 0, ×200) and ERCC1-positive sections (H-score: 15 and 200, ×200). (C) Kaplan–Meier analysis of overall survival (OS) according to TS expression, determined using a cut-off point of median H-score 25. (D) Kaplan–Meier analysis of OS according to ERCC1 expression, determined using a cut-off point of median H-score 60.

    Article Snippet: Immunohistochemical staining was carried out using the D6G6 anti-excision repair cross-complementation group 1 (ERCC1) monoclonal antibody (Cell Signaling Technology, Danvers, MA), the TS106 anti-TS monoclonal antibody (Dako, Glostrup, Denmark), and a DAKO Link 48 system (Dako).

    Techniques: Expressing, Immunohistochemistry